MX2008014654A - Formulacion de liberacion lenta de estradiol-progesterona para anticoncepción y terapia de remplazo hormonal. - Google Patents
Formulacion de liberacion lenta de estradiol-progesterona para anticoncepción y terapia de remplazo hormonal.Info
- Publication number
- MX2008014654A MX2008014654A MX2008014654A MX2008014654A MX2008014654A MX 2008014654 A MX2008014654 A MX 2008014654A MX 2008014654 A MX2008014654 A MX 2008014654A MX 2008014654 A MX2008014654 A MX 2008014654A MX 2008014654 A MX2008014654 A MX 2008014654A
- Authority
- MX
- Mexico
- Prior art keywords
- estradiol
- particles
- water
- cholesterol
- progesterone
- Prior art date
Links
- 229960005309 estradiol Drugs 0.000 title claims abstract description 122
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims abstract description 114
- 229930182833 estradiol Natural products 0.000 title claims abstract description 96
- 239000002245 particle Substances 0.000 title claims abstract description 96
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 74
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 67
- 230000008569 process Effects 0.000 title description 30
- 238000004519 manufacturing process Methods 0.000 title description 12
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract description 189
- 239000000203 mixture Substances 0.000 claims abstract description 105
- 238000009472 formulation Methods 0.000 claims abstract description 79
- 229960003387 progesterone Drugs 0.000 claims abstract description 78
- 239000000186 progesterone Substances 0.000 claims abstract description 78
- 238000004090 dissolution Methods 0.000 claims abstract description 29
- 229940088597 hormone Drugs 0.000 claims description 55
- 239000005556 hormone Substances 0.000 claims description 55
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000012298 atmosphere Substances 0.000 claims description 23
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000008901 benefit Effects 0.000 abstract description 8
- 238000002657 hormone replacement therapy Methods 0.000 abstract description 6
- VBKJKYFABSYSJQ-IWGYNEQTSA-N (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one (8R,9S,13S,14S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 VBKJKYFABSYSJQ-IWGYNEQTSA-N 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 description 97
- 229940011871 estrogen Drugs 0.000 description 39
- 239000000262 estrogen Substances 0.000 description 39
- 239000000583 progesterone congener Substances 0.000 description 35
- 238000002425 crystallisation Methods 0.000 description 28
- 230000008025 crystallization Effects 0.000 description 28
- BPWVLVILKNHVFL-IDQWTGRXSA-N OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BPWVLVILKNHVFL-IDQWTGRXSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 20
- 230000002254 contraceptive effect Effects 0.000 description 13
- 239000008135 aqueous vehicle Substances 0.000 description 12
- 230000027758 ovulation cycle Effects 0.000 description 11
- 230000003054 hormonal effect Effects 0.000 description 10
- 230000016087 ovulation Effects 0.000 description 10
- 230000003111 delayed effect Effects 0.000 description 9
- 230000002035 prolonged effect Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003433 contraceptive agent Substances 0.000 description 8
- 210000004696 endometrium Anatomy 0.000 description 8
- 238000010255 intramuscular injection Methods 0.000 description 8
- 239000007927 intramuscular injection Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002357 endometrial effect Effects 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 description 5
- 108010073521 Luteinizing Hormone Proteins 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940040129 luteinizing hormone Drugs 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002226 simultaneous effect Effects 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004246 corpus luteum Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 239000003688 hormone derivative Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003575 estradiol acetate Drugs 0.000 description 2
- 229950010215 estradiol dipropionate Drugs 0.000 description 2
- RFWTZQAOOLFXAY-BZDYCCQFSA-N estradiol enanthate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 RFWTZQAOOLFXAY-BZDYCCQFSA-N 0.000 description 2
- TXHUMRBWIWWBGW-GVGNIZHQSA-N estradiol undecylate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 TXHUMRBWIWWBGW-GVGNIZHQSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000001456 gonadotroph Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-QXDIGNSFSA-N (8s,9r,13r,14r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@@H]3CC[C@@](C)([C@@H](CC4)O)[C@H]4[C@H]3CCC2=C1 VOXZDWNPVJITMN-QXDIGNSFSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- JQIYNMYZKRGDFK-RUFWAXPRSA-N Estradiol dipropionate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 JQIYNMYZKRGDFK-RUFWAXPRSA-N 0.000 description 1
- TXHUMRBWIWWBGW-UHFFFAOYSA-N Estradiol undecylate Natural products C1CC2=CC(O)=CC=C2C2C1C1CCC(OC(=O)CCCCCCCCCC)C1(C)CC2 TXHUMRBWIWWBGW-UHFFFAOYSA-N 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VQHQLBARMFAKSV-AANPDWTMSA-N [(8r,9s,13s,14s,17s)-3-acetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 VQHQLBARMFAKSV-AANPDWTMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 150000005690 diesters Chemical group 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000028801 embryonic cleavage Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229960005416 estradiol cypionate Drugs 0.000 description 1
- 229950004659 estradiol enanthate Drugs 0.000 description 1
- 229950005281 estradiol undecylate Drugs 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47793903P | 2003-06-13 | 2003-06-13 | |
| PCT/IB2004/001930 WO2004110408A2 (en) | 2003-06-13 | 2004-06-10 | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008014654A true MX2008014654A (es) | 2009-03-09 |
Family
ID=33551788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008014654A MX2008014654A (es) | 2003-06-13 | 2004-06-10 | Formulacion de liberacion lenta de estradiol-progesterona para anticoncepción y terapia de remplazo hormonal. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7589082B2 (enExample) |
| EP (3) | EP1663161B1 (enExample) |
| JP (2) | JP4956185B2 (enExample) |
| CN (2) | CN100594907C (enExample) |
| AT (1) | ATE454885T1 (enExample) |
| AU (1) | AU2004246870B2 (enExample) |
| BR (1) | BRPI0411335A (enExample) |
| CA (2) | CA2528545C (enExample) |
| CY (1) | CY1109967T1 (enExample) |
| DE (1) | DE602004025156D1 (enExample) |
| DK (3) | DK1844765T3 (enExample) |
| EA (3) | EA012783B1 (enExample) |
| ES (3) | ES2537551T3 (enExample) |
| HU (1) | HUE025147T2 (enExample) |
| IL (2) | IL172466A (enExample) |
| MX (1) | MX2008014654A (enExample) |
| NO (1) | NO341540B1 (enExample) |
| OA (1) | OA13307A (enExample) |
| PL (3) | PL1820494T3 (enExample) |
| PT (3) | PT1663161E (enExample) |
| SI (3) | SI1844765T1 (enExample) |
| TW (1) | TWI336623B (enExample) |
| WO (1) | WO2004110408A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7589082B2 (en) | 2003-06-13 | 2009-09-15 | Skendi Finance Ltd | Pharmaceutical formulation for contraception and hormone-replacement therapy |
| CN102056611A (zh) * | 2008-04-14 | 2011-05-11 | Posi维森纳里解决方案有限责任公司 | 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物 |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| WO2012129305A1 (en) * | 2011-03-23 | 2012-09-27 | Pop Test Cortisol Llc | Combination therapy |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| ITUB20153652A1 (it) * | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR20180123165A (ko) * | 2016-04-01 | 2018-11-14 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| PL3272732T3 (pl) | 2016-07-19 | 2020-03-31 | Evonik Degussa Gmbh | Sposób alkoksykarbonylowania etylenowo nienasyconych związków za pomocą ligandów monofosfinowych |
| KR102954589B1 (ko) * | 2018-11-29 | 2026-04-20 | 인시그나 인크. | 불임제로서의 에스트라디올 벤조에이트 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| EP3954364A1 (en) | 2020-08-14 | 2022-02-16 | Chemo Research, S.L. | New modified release oral contraceptive composition |
| US12691126B2 (en) | 2022-05-26 | 2026-07-28 | Insigna Inc. | Non-surgical prevention of unpleasant odor in meats and aggressive or sexual behavior in male ruminants |
| US11938140B2 (en) | 2022-05-26 | 2024-03-26 | Insigna Inc. | Non-surgical prevention of boar taint and aggressive behavior |
| US12691125B2 (en) | 2022-05-26 | 2026-07-28 | Insigna, Inc. | Prevention of estrus in sow and ruminants |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| GB1367608A (en) * | 1973-03-09 | 1974-09-18 | Biolog Concepts Inc | Oral pharmaceutical dosage form |
| US4218255A (en) * | 1976-08-30 | 1980-08-19 | University Of Dayton | Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method |
| US4180560A (en) * | 1976-10-26 | 1979-12-25 | Syntex Corporation | Inert core implant pellet |
| JPS5799562A (en) | 1980-12-12 | 1982-06-21 | Nippon Shinyaku Co Ltd | Preparation of microcrystal |
| US5023092A (en) | 1988-06-16 | 1991-06-11 | Ici Americas Inc. | Mannitol having gamma sorbitol polymorph |
| IT1230566B (it) | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| FR2663224B1 (fr) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| FR2663223B1 (fr) | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| IE71203B1 (en) * | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| IE62665B1 (en) * | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| DE4130173A1 (de) | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
| SE9301171D0 (sv) * | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
| TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| FR2747042B1 (fr) | 1996-04-05 | 1998-06-05 | Besins Iscovesco Lab | Medicament a base de progesterone et d'oestradiol |
| US5762956A (en) * | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| EP0888790A1 (en) | 1997-07-04 | 1999-01-07 | PowderJect Research Limited | Drug particle delivery device |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| EP1591121B1 (en) * | 2000-12-14 | 2009-06-24 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| US7589082B2 (en) | 2003-06-13 | 2009-09-15 | Skendi Finance Ltd | Pharmaceutical formulation for contraception and hormone-replacement therapy |
-
2004
- 2004-06-10 US US10/864,470 patent/US7589082B2/en not_active Expired - Fee Related
- 2004-06-10 CN CN200480023175A patent/CN100594907C/zh not_active Expired - Fee Related
- 2004-06-10 PT PT47365457T patent/PT1663161E/pt unknown
- 2004-06-10 OA OA1200500357A patent/OA13307A/en unknown
- 2004-06-10 PT PT07008942T patent/PT1820494E/pt unknown
- 2004-06-10 EP EP20040736545 patent/EP1663161B1/en not_active Expired - Lifetime
- 2004-06-10 EP EP20070008942 patent/EP1820494B1/en not_active Expired - Lifetime
- 2004-06-10 SI SI200432238T patent/SI1844765T1/sl unknown
- 2004-06-10 DK DK07008938.8T patent/DK1844765T3/en active
- 2004-06-10 PL PL07008942T patent/PL1820494T3/pl unknown
- 2004-06-10 EA EA200600029A patent/EA012783B1/ru not_active IP Right Cessation
- 2004-06-10 MX MX2008014654A patent/MX2008014654A/es active IP Right Grant
- 2004-06-10 BR BRPI0411335 patent/BRPI0411335A/pt not_active Application Discontinuation
- 2004-06-10 DE DE200460025156 patent/DE602004025156D1/de not_active Expired - Lifetime
- 2004-06-10 ES ES04736545.7T patent/ES2537551T3/es not_active Expired - Lifetime
- 2004-06-10 EA EA200900451A patent/EA018356B1/ru not_active IP Right Cessation
- 2004-06-10 AU AU2004246870A patent/AU2004246870B2/en not_active Ceased
- 2004-06-10 EA EA201201221A patent/EA026709B1/ru not_active IP Right Cessation
- 2004-06-10 WO PCT/IB2004/001930 patent/WO2004110408A2/en not_active Ceased
- 2004-06-10 AT AT07008942T patent/ATE454885T1/de active
- 2004-06-10 CN CN200910258692.9A patent/CN101816662B/zh not_active Expired - Fee Related
- 2004-06-10 DK DK04736545.7T patent/DK1663161T3/en active
- 2004-06-10 CA CA2528545A patent/CA2528545C/en not_active Expired - Fee Related
- 2004-06-10 ES ES07008942T patent/ES2340422T3/es not_active Expired - Lifetime
- 2004-06-10 PL PL07008938T patent/PL1844765T3/pl unknown
- 2004-06-10 PL PL04736545T patent/PL1663161T3/pl unknown
- 2004-06-10 PT PT70089388T patent/PT1844765E/pt unknown
- 2004-06-10 CA CA2849228A patent/CA2849228C/en not_active Expired - Fee Related
- 2004-06-10 JP JP2006516535A patent/JP4956185B2/ja not_active Expired - Fee Related
- 2004-06-10 HU HUE04736545A patent/HUE025147T2/hu unknown
- 2004-06-10 DK DK07008942T patent/DK1820494T3/da active
- 2004-06-10 EP EP20070008938 patent/EP1844765B1/en not_active Expired - Lifetime
- 2004-06-10 SI SI200432235T patent/SI1663161T1/sl unknown
- 2004-06-10 SI SI200431384T patent/SI1820494T1/sl unknown
- 2004-06-10 ES ES07008938.8T patent/ES2537563T3/es not_active Expired - Lifetime
- 2004-06-14 TW TW93117058A patent/TWI336623B/zh not_active IP Right Cessation
-
2005
- 2005-12-08 IL IL172466A patent/IL172466A/en active IP Right Grant
-
2006
- 2006-01-13 NO NO20060200A patent/NO341540B1/no not_active IP Right Cessation
-
2008
- 2008-12-02 US US12/326,316 patent/US8163722B2/en not_active Expired - Fee Related
-
2010
- 2010-04-12 CY CY101100328T patent/CY1109967T1/el unknown
-
2011
- 2011-01-25 IL IL210851A patent/IL210851A/en active IP Right Grant
- 2011-04-06 JP JP2011084716A patent/JP2011157386A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8163722B2 (en) | Pharmaceutical formulation for contraception and hormone-replacement therapy | |
| SG184111A1 (en) | Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis | |
| US20030195177A1 (en) | Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy | |
| MXPA05013507A (es) | Formulacion de liberacion lenta de estradiol-progesterona paraanticoncepcion y terapia de reemplazo hormonal | |
| HK1109586B (en) | Slow release estradiol-progesterone formulation | |
| HK1106717B (en) | Microparticles consisting of estradiol and cholesterol | |
| HK1097735B (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol | |
| HK1147426B (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |